Multiply Labs raises $75 million Series B to use robots for gene therapy drug production

YC announced that its S16-incubated Multiply Labs has closed a $75 million Series B round. The company builds robots for producing complex drugs, covering gene therapies and mRNA therapies. The original article notes that AI has accelerated drug discovery, but drug production is still mostly manual, slow, and prone to contamination, with some gene therapies costing over $1 million per dose; Multiply's robots are already running this production line in AstraZeneca and Legend Biotech factories.